COMMUNIQUÉS West-GlobeNewswire

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
08/05/2025
Please see enclosed pdf. Attachment 08052025_trading_in_shares_GL
Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202
08/05/2025
Video illustrates SENTI-202’s MoA, namely to selectively kill both AML blasts and leukemic stem cells (LSCs) while protecting healthy hematopoietic stem cells/ hematopoietic stem and progenitor cells (HSC/HSPCs) using [...]
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value
08/05/2025
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical [...]
HepaRegeniX Scientific Founder Covers HRX-215 Development and Clincial Data in Plenary at the European Association for the Study of the Liver Congress 2025
08/05/2025
Prof. Lars Zender’s featured talk described HepaRegeniX’s lead candidate and its potential in increasing liver regeneration, from initial target discovery and drug development towards Phase Ia clinical trial results [...]
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
08/05/2025
Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase 1 ASPEN-CRC [...]
Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset
08/05/2025
New patent filing secures composition of matter protection for AZD5904, a potent myeloperoxidase inhibitor in Conduit’s pipeline, unlocking up to 20 years of new IP runway and enabling enhanced formulation strategies to [...]
Lifeward Completes Research Program with Israeli Human-Robot Interaction Consortium to Integrate Artificial Intelligence and Exoskeletons
08/05/2025
Three-year program examined opportunities to integrate artificial intelligence technology into future generations of ReWalk Exoskeletons MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- [...]
Exagen Inc. Prices Public Offering of Common Stock
08/05/2025
CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3 [...]
Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration
08/05/2025
Meeting to Take Place on July 25, 2025 Meeting’s Purpose is To Discuss Upcoming Clinical Development Plan and Protocol Designs GLEN ALLEN, Va., May 08, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. ( NASDAQ: ADIL [...]
Arialief Complaints Exposed: 2025 User Reviews Analyzed and Verified
08/05/2025
Arialief for Neuropathy is a doctor-recommended joint support supplement made with natural, clinically backed ingredients like turmeric, glucosamine, and Boswellia. Designed to reduce inflammation, relieve joint pain, [...]
STRATA Skin Sciences to Participate in the D. Boral Capital Inaugural Global Conference
08/05/2025
HORSHAM, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative [...]
Yamo Pharma Presents Statistically Significant Phase 2 Autism Results for L1-79 at INSAR 2025
08/05/2025
Trial achieves unprecedented and clinically meaningful socialization gains in adolescents and young adults, addressing core autism symptoms currently lacking FDA-approved therapies NEW YORK, May 08, 2025 (GLOBE NEWSWIRE [...]
Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
08/05/2025
Reported positive interim results demonstrating durable responses in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 in NMIBC Results from planned interim analysis of approximately 25 six-month evaluable BCG- [...]
ORYZON Awarded €13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)
08/05/2025
Approximately 15 million USD Oryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases Oryzon will explore Aggression in specific subsets of Autism Spectrum Disorder [...]
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights
08/05/2025
IND clearance and initiation of global basket trial exploring AlloNK ® + rituximab in refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies and systemic sclerosis First trial to explore [...]
Pathos AI Appoints Iker Huerga as Chief Executive Officer to Lead the Next Era of AI-Enabled Drug Development
08/05/2025
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Pathos AI, a leading AI-enabled biotech company focused on transforming drug development in oncology, today announced the appointment of Iker Huerga as Chief Executive Officer [...]
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
08/05/2025
– EMA submission expected in 2H25 by partner Menarini – – PREVAIL Phase 3 CVOT remains on track – -- BROADWAY and TANDEM results presented at EAS with simultaneous publications in the New England Journal of Medicine and [...]
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update
08/05/2025
Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (ORR), including one [...]
Stryker declares an $0.84 per share quarterly dividend
08/05/2025
Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the [...]

Pages